United TherapeuticsFRA:UTH -2.65%82 OCF Margin % is 59.28% as of Mar. 2026, which is 42% above its 10-year median of 41.74. GuruFocus rates FRA:UTH with a GF Score™ of 82/100 and a GF Value™ of €337.25 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, United Therapeutics ranks better than 97.91% on this metric.
The historical rank and industry rank for United Therapeutics's OCF Margin % or its related term are showing as below:
FRA:UTH'
s OCF Margin % Range Over the Past 10 Years
Min: -14.26 Med: 41.74 Max: 50.95
Current: 49.24
During the past 13 years, the highest OCF Margin % of United Therapeutics was 50.95%. The lowest was -14.26%. And the median was 41.74%.
FRA:UTH's OCF Margin % is ranked better than 97.91% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs FRA:UTH: 49.24
United Therapeutics OCF Margin % Related Terms
United Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a OCF Margin % of 59.28% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on United Therapeutics and its competitors. This is 42% above median its historical median of 41.74. According to the industry distribution chart, United Therapeutics ranks #20 out of 959 companies in the Drug Manufacturers industry, placing it in the top 2.1%.
Is United Therapeutics' OCF Margin % too high?
United Therapeutics' current OCF Margin % of 59.28% is 42% above median its 10-year median of 41.74. The Drug Manufacturers industry median OCF Margin % is 9.94. United Therapeutics' value of 59.28% is 496.4% above this industry median. Based on the distribution chart, United Therapeutics ranks #20 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' OCF Margin % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #20 out of 959 companies for OCF Margin %. This places United Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. United Therapeutics' value of 59.28% is 496.4% above this benchmark. While the company's 10-year median is 41.74 vs. the industry median of 9.94, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current OCF Margin % of 59.28% is 496.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current OCF Margin % is 59.28%, which is 42% above median its own 10-year median of 41.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €337.25, compared to a current price of €473.30 — trading 40.3% above its estimated fair value. The current OCF Margin % is 59.28%, which is 42% above median its 10-year median of 41.74 and 496.4% above the Drug Manufacturers industry median of 9.94. United Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current OCF Margin % is 59.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €473.30 is trading 40.3% above its estimated GF Value™ of €337.25.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
OCF Margin %: 59.28% (42% above median its 10-year median of 41.74)
GF Value™: €337.25 vs. price of €473.30 (40.3% above fair value)
Industry Position: 496.4% above the Drug Manufacturers median (#20 of 959)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
82GF Score
Get the complete analysis for FRA:UTH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
